• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Thermo Fisher inks deals with Daiichi and Takeda

biospectrumasiaMay 03, 2018

Tag: Thermo Fisher , Daiichi , Takeda

Thermo Fisher Scientific has entered into agreements with Daiichi Sankyo and Takeda Pharmaceutical aimed at expanding the utility of its Oncomine Dx Target Test to support each firm's clinical trials and development programs.

Thermo Fisher, committed to advancing development of Oncomine Dx as a companion diagnostic for multiple drugs, will retain global commercialization rights to the test and lead all regulatory submissions.

It has also closed a similar CDx deal with Spectrum Pharmaceuticals to support poziotinib in NSCLC.

Last year, Thermo Fisher inked CDx agreements with Agios Pharmaceuticals and Blueprint Medicines.

Register as Visitor to CPhI China 2018!

Previous:Cellmid inks deal with China's Fukangren Bio-pharm

Next:Ironwood Pharma to split into two entities

Related News

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

SCG Cell Therapy Pte Ltd (SCG),announced the signing of a Memorandum of Understanding (MoU) with A*STAR BTI and NATi to advance RNA-based therapeutics manufacturing process development and clinical translation.

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Thermo Fisher inks deals with Daiichi and Takeda | Pharmasources.com

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins
CEFIXIME cephalosporins

CEFIXIME cephalosporins
CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins
CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins
CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service